Last updated on November 2018

Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy


Brief description of study

The purpose of this study is to evaluate the tolerability, safety and the pharmacokinetic (PK) profile of daratumumab in Chinese participants with relapsed or refractory multiple myeloma (RRMM) who failed at least 2 prior lines of systemic therapy (Part 1 and Part 2); and to evaluate the tolerability and safety of daratumumab in Chinese participants whose prior therapy included a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) and who have demonstrated disease progression on the last therapy (Part 3).

Clinical Study Identifier: NCT02852837

Contact Investigators or Research Sites near you

Start Over

Use link at the bottom ...

Peking University Third Hospital
Beijing, China

Use link at the bottom ...

First Affiliated Hospital, Medical School of Zhejiang University
Hangzhou, China

Use link at the bottom ...

Ruijin Hospital, Shanghai Jiao Tong University
Shanghai, China

Use link at the bottom ...

Institute of Hematology & Blood Diseases Hospital
Tianjin, China, China

Use link at the bottom ...

Guangdong General Hospital
Guangzhou, China

Use link at the bottom ...

The First Affliated Hospital of Soochow University
Suzhou, China

Use link at the bottom ...

Xinqiao Hospital of the Third Military Medical University
Chongqing, China

Use link at the bottom ...

Tianjin cancer hospital
Tianjin, China

Use link at the bottom ...

Henan Cancer Hospital
Zhengzhou, China